Living with a chronic inflammatory disease like psoriatic arthritis means taking care of your mental health. Here’s what to know about monitoring mental health issues in PsA, and how to incorporate mental health treatment into your overall PsA management.
Up to 30 percent of psoriasis patients will eventually develop psoriatic arthritis (PsA), though researchers are unclear why. But a new study suggests how you treat your psoriasis might have a major impact on whether you develop PsA.
A new study from the ArthritisPower research registry found that psoriatic arthritis (PsA) greatly impacts patients' ability to be physically active and live independently, and they want their treatment plan to help improve those aspects of life.
When compared to patients with rheumatoid arthritis (RA), people with psoriatic arthritis (PsA) or psoriasis were more likely to develop liver disease when taking methotrexate, new research showed.
A new study found that continued use of IL-17 inhibitors may help psoriatic arthritis (PsA) patients maintain minimal disease activity (MDA).
A phase 3 clinical trial tested the effectiveness of upadacitinib (Rinvoq), a new JAK inhibitor, and found it may be another treatment option for patients with psoriatic arthritis (PsA).
Fatigue is notoriously challenging for psoriatic arthritis patients and their doctors to discuss and manage, but better care starts with better communication.
Seeing a rheumatologist or dermatologist over telehealth can be a great way to stay on top of your psoriasis or psoriatic arthritis during the COVID-19 pandemic. Here’s what to expect and how to prepare for an optimal visit.
Tremfya, already approved for psoriasis, inhibits an immune system protein called IL-23 that can lead to inflammation.
Approved in 2019 for moderate to severe rheumatoid arthritis, the drug may offer an oral alternative to infused or injected biologics.
In a ‘head-to-head’ clinical trial, Cosentyx, an IL-17 inhibitor, cleared skin better than Humira and it did just as well treating joint problems.
Already approved for psoriasis, the IL-23 inhibitor is looking good for patients with psoriatic arthritis.
Drugs that block the immune system protein IL-17 may work better for clearing skin plaques than those that block TNF.
It may be the case that psoriatic arthritis isn’t treated as aggressively as other inflammatory arthritis, like rheumatoid arthritis.
Psoriatic arthritis is linked with an increased fracture risk, but taking biologic medication can help.
The medication is already FDA-approved to treat psoriasis.
There are many drug options for managing active PsA. Here’s what happened when a study compared them with each other.
A ‘step-up’ approach, or starting with milder drugs first, seems to reduce your chances of hitting remission.
In addition to medication, a proper skin care routine can go a long way toward managing the psoriasis plaques in psoriatic arthritis.
PASDAS is a new assessment tool that uses patient feedback about quality of life in addition to physician evaluations.
Here’s what medications doctors are likely to prescribe for PsA first.
A small initial study was promising, but more research is needed.
People with psoriatic arthritis (PsA) are often prescribed methotrexate, an anti-TNF drug like etanercept (Enbrel), or a combination of both. Which option is most effective?
Some psoriatic arthritis patients may be able to take a common TNF inhibitor drug less frequently and still maintain remission.
On Dec. 14, Pfizer, which makes tofacitinib (Xeljanz), announced that the FDA had approved the drug for PsA.
The U.S. Food and Drug Administration is currently reviewing Simponi, an intravenous TNF-inhibitor, for psoriatic arthritis and ankylosing spondylitis patients.